| Client: | A mid-size pharmaceutical company conducting four simultaneous international studies in multiple myeloma. The 18-month enrollment goal of the four studies was 1,100 patients across 200 sites located in North America, Western Europe, Eastern Europe, and Australia. |
| Challenge: | The programs faced three major challenges: simultaneously launching four large, full-service multinational trials; maintaining investigative-site motivation throughout the projected patient enrollment period; and developing effective drug-distribution strategies due to an initial shortage of study drug. |
| Solutions: | Identify areas of commonality among the programs to maximize efficiencies and shorten start-up timelines. Maintain close contact with investigators and study coordinators to sustain motivation. Implement a site-by-site distribution plan to ensure adequate drug availability for those sites actively enrolling patients. |
| Outcome: | Enrollment was completed ahead of schedule. Data from these studies resulted in regulatory approvals in the US and Europe. |
 |
||
 |
In Phase II-IV PharmaNet offers all the clinical development services traditionally associated with conducting Phase II-IV programs. A key differentiating factor of PharmaNet is that in every program we conduct, PharmaNet provides an unrivaled combination of experienced project-management teams, senior management oversight, and an exclusive approach to building relationships with sponsors. |
 |
 |
||
Managing Multiple, Multinational Programs for A Single Sponsor
PharmaNet Development Group, Inc.
504 Carnegie Center, Princeton, NJ 08540Tel 609 951 6800Fax 609 514 0390
504 Carnegie Center, Princeton, NJ 08540Tel 609 951 6800Fax 609 514 0390
© 2008 PharmaNet Development Group, Inc. All rights reserved.